文献速递特殊人群用药抗栓抗凝管理

低体重患者使用Xa因子抑制剂的有效性与安全性

Efficacy and safety of factor Xa inhibitors in low body weight patients.
PubMed 文献 · Pharmacotherapy · 2023-11-14

本研究为多中心回顾性队列研究,纳入2538例低体重(体重≤60 kg或BMI<18.5 kg/m²)因房颤或静脉血栓栓塞接受治疗的患者,比较Xa因子抑制剂(阿哌沙班或利伐沙班)与华法林。结果显示两组大出血、血栓栓塞、复合出血及全因死亡率均无显著差异,支持低体重患者使用Xa因子抑制剂。

要点

  • 低体重患者使用Xa因子抑制剂大出血风险与华法林无显著差异(HR 1.03)。
  • 血栓栓塞、复合出血及全因死亡率在两组间亦无显著差异。
  • 结果为低体重患者使用Xa因子抑制剂提供了鼓励性证据。

核心结论

  • 低体重患者使用Xa因子抑制剂与华法林在安全性和有效性方面未观察到差异。

主要发现

  • 控制潜在混杂因素后大出血时间无显著差异(HR 1.03,95%CI 0.70-1.53,p=0.87),倾向性评分匹配后结果相似。
  • Xa因子抑制剂组与华法林组血栓栓塞发生率分别为5.3%与6.2%(p=0.38)。
  • 复合大出血+临床相关非大出血发生率分别为9.8%与11.5%(p=0.18)。
  • 全因死亡率分别为10.7%与12.8%(p=0.12)。

临床怎么用

  • 对于体重≤60 kg或BMI<18.5 kg/m²的房颤或静脉血栓栓塞患者,可考虑使用Xa因子抑制剂(阿哌沙班或利伐沙班)作为华法林的替代选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: The purpose of this study is to provide evidence for the safety and efficacy of factor Xa inhibitors in patients with a weight ≤60 kg or BMI < 18.5 kg/m2 . DESIGN: Multicenter, retrospective, cohort study. SETTING: Twenty-two Ascension Health hospitals. PATIENTS: Low-body-weight adult patients (weight ≤ 60 kg or BMI < 18.5 kg/m2 ) receiving treatment for atrial fibrillation or venous thromboembolism. INTERVENTION: Factor Xa inhibitors (apixaban or rivaroxaban) or warfarin. MEASUREMENTS AND MAIN RESULTS: This study included 2538 patients between the factor Xa inhibitors (n = 1695) and warfarin (n = 843) groups with a mean weight of 53.5 ± 5.5 kg and BMI of 20.7 ± 3.1 kg/m2 . No significant difference in time to major bleeding was noted after controlling for potential confounders (HR 1.03, 95% CI 0.70-1.53, p = 0.87); similar results were seen following propensity score matching. Thromboembolism (5.3% vs. 6.2%, p = 0.38), composite major + clinically relevant nonmajor bleeding (9.8% vs. 11.5%, p = 0.18), and all-cause mortality (10.7% vs. 12.8%, p = 0.12) were similar between patients receiving factor Xa inhibitors versus warfarin. CONCLUSION: No differences in safety or effectiveness were noted between factor Xa inhibitors versus warfarin. These findings provide encouraging evidence to support the use of factor Xa inhibitors in low-body-weight patients.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Tan Y, Hubbard C, Owens H, et al. Efficacy and safety of factor Xa inhibitors in low body weight patients. Pharmacotherapy. 2023. PMID: 37926690. doi:10.1002/phar.2888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。